Zoetis is the world's largest animal health company, generating $9.5 billion in 2025 revenue (+6% organic operational) with adjusted net income of $2.8 billion. Companion animal $4.2 billion (+4%), livestock $2.72 billion (+8%, third consecutive year of growth). Simparica Trio surpassed $1 billion in U.S. sales; Apoquel and Cytopoint sustained double-digit growth. Zoetis returned $4.1 billion to shareholders in 2025.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Strategic priorities for 2026 include the pivot toward feline chronic kidney disease ($3-4 billion addressable opportunity), companion animal oncology expansion, and Vanguard Recombishield and Leniva launches (canine OA pain mAb approved in Canada October 2025). 2026 guidance: $9.825-10.025 billion revenue (+3-5% organic operational). Strengths include category leadership across nearly every animal health segment, the most productive R&D pipeline in the industry, and disciplined capital return. Risks include the Phibro MFA divestiture removing $200M+ revenue, mature parasiticide competition, and FX headwinds.

Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook